Targets › HLA-B
2 programs from 1 company in 2 trials: 2 Phase 1; Genitourinary, Oncology; next expected readout Dec 2027.
Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-B-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells. (UniProt, P01889)
Open in Phaseline: the race on HLA-B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC | Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney CRISPR-Cas9 ribonucleoprotein complexes targeting HLA-A, HLA-B, and CIITA to knock out HLA | HLA-A, HLA-B, CIITA | Phase 1 | End-Stage Renal Disease | Dec 2027 |
| AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC | Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver CRISPR-Cas9 RNP complex targeting HLA-A, HLA-B, and CIITA to create hypoimmunogenic graft | HLA-A, HLA-B, CIITA | Phase 1 | Liver Diseases | Dec 2027 |
End-Stage Renal Disease (1) Liver Diseases (1)
other (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.